About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: KVUE )

23.68 +0.71 (+3.09%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,635,450
Open 22.87
Bid (Size) 23.55 (9)
Ask (Size) 23.89 (1)
Prev. Close 22.97
Today's Range 22.84 - 23.72
52wk Range 17.67 - 23.72
Shares Outstanding N/A
Dividend Yield 0.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Wants To Pull Popular OTC Decongestant Used For Common Cold Over Effectiveness Concerns
FDA proposes removing oral phenylephrine from OTC drugs for nasal congestion, citing ineffectiveness. Public comments open before a final order is issued. 
Via Benzinga
Exposures Product Safety
Kenvue (KVUE) Q3 2024 Earnings Call Transcript
KVUE earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
+9.78%
+9.78%
1 Month
+9.99%
+9.99%
3 Month
+12.65%
+12.65%
6 Month
+15.29%
+15.29%
1 Year
+23.20%
+23.20%

More News

Read More
Listerine And Tylenol Maker Kenvue's Q3 Earnings: Revenue Miss On Weak Skin Health And Beauty Sales
Via Benzinga
Kenvue Reports Third Quarter 2024 Results
From Kenvue
Via Business Wire
Neutrogena® Launches Breakthrough Collaboration with Two of World’s Most Recognizable Dermatologists
From Kenvue
Via Business Wire
Is Kenvue Stock a Buy Now?
Via The Motley Fool
10 Analysts Have This To Say About Kenvue
Via Benzinga
Navigating 10 Analyst Ratings For Kenvue
Via Benzinga
This Big New Development Could Be Bullish for Kenvue Stock
Via The Motley Fool
3 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.
Via The Motley Fool
Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months
Via The Motley Fool
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Via Investor's Business Daily
Nvidia Among Five Best S&P 500 Stocks Today
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Dow Drops 320 Points as Stocks Cool Off
Via Talk Markets
Topics Stocks
Exposures US Equities
What's Going On With Kenvue Stock Monday?
Via Benzinga
Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday?
Via Benzinga
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump
Via Talk Markets
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
Via Benzinga
Kenvue to Announce Third Quarter 2024 Results on November 7, 2024
From Kenvue
Via Business Wire
Kenvue Declares Quarterly Cash Dividend
From Kenvue
Via Business Wire
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Via MarketBeat
Exposures COVID-19
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
Via The Motley Fool
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.